IN2013DN02552A - - Google Patents

Download PDF

Info

Publication number
IN2013DN02552A
IN2013DN02552A IN2552DEN2013A IN2013DN02552A IN 2013DN02552 A IN2013DN02552 A IN 2013DN02552A IN 2552DEN2013 A IN2552DEN2013 A IN 2552DEN2013A IN 2013DN02552 A IN2013DN02552 A IN 2013DN02552A
Authority
IN
India
Prior art keywords
ht2c
benzazepine
tetrahydro
chloro
salts
Prior art date
Application number
Other languages
English (en)
Inventor
Anthony C Blackburn
Scott Stirn
Yun Shan
Anna Shifrina
Original Assignee
Arena Pharm Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Arena Pharm Inc filed Critical Arena Pharm Inc
Publication of IN2013DN02552A publication Critical patent/IN2013DN02552A/en

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D223/00Heterocyclic compounds containing seven-membered rings having one nitrogen atom as the only ring hetero atom
    • C07D223/14Heterocyclic compounds containing seven-membered rings having one nitrogen atom as the only ring hetero atom condensed with carbocyclic rings or ring systems
    • C07D223/16Benzazepines; Hydrogenated benzazepines
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/04Anorexiants; Antiobesity agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Child & Adolescent Psychology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Other In-Based Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
IN2552DEN2013 2010-09-01 2011-08-31 IN2013DN02552A (enrdf_load_html_response)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US40258910P 2010-09-01 2010-09-01
PCT/US2011/049953 WO2012030951A1 (en) 2010-09-01 2011-08-31 Fast-dissolve dosage forms of 5-ht2c agonists

Publications (1)

Publication Number Publication Date
IN2013DN02552A true IN2013DN02552A (enrdf_load_html_response) 2015-08-07

Family

ID=44645827

Family Applications (1)

Application Number Title Priority Date Filing Date
IN2552DEN2013 IN2013DN02552A (enrdf_load_html_response) 2010-09-01 2011-08-31

Country Status (11)

Country Link
US (1) US20140148442A1 (enrdf_load_html_response)
EP (1) EP2611781A1 (enrdf_load_html_response)
JP (1) JP2013536858A (enrdf_load_html_response)
KR (1) KR20130138768A (enrdf_load_html_response)
CN (1) CN103189358A (enrdf_load_html_response)
AU (1) AU2011296027A1 (enrdf_load_html_response)
CA (1) CA2808900A1 (enrdf_load_html_response)
IN (1) IN2013DN02552A (enrdf_load_html_response)
MX (1) MX2013002430A (enrdf_load_html_response)
SG (2) SG10201506873WA (enrdf_load_html_response)
WO (1) WO2012030951A1 (enrdf_load_html_response)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20130101524A (ko) 2010-09-01 2013-09-13 아레나 파마슈티칼스, 인크. 5-ht2c 아고니스트의 비-흡습성 염
AU2011296015B2 (en) 2010-09-01 2015-11-12 Arena Pharmaceuticals, Inc. Administration of lorcaserin to individuals with renal impairment
US9248133B2 (en) 2010-09-01 2016-02-02 Arena Pharmaceuticals, Inc. Salts of lorcaserin with optically active acids
CA2808912C (en) 2010-09-01 2019-09-17 Zezhi Jesse Shao Modified-release dosage forms of 5-ht2c agonists useful for weight management
WO2014058441A1 (en) 2012-10-09 2014-04-17 Arena Pharmaceuticals, Inc. Method of weight management
WO2014135545A1 (en) * 2013-03-05 2014-09-12 Sandoz Ag Solid dispersion comprising amorphous lorcaserin hydrochloride
CN105431415A (zh) * 2013-05-20 2016-03-23 斯洛文尼亚莱柯制药股份有限公司 通过烯烃的弗瑞德-克来福特烷基化进行的8-氯-3-苯并[d]氮杂*的新合成方法
EP2868656A1 (en) * 2013-11-05 2015-05-06 LEK Pharmaceuticals d.d. Stabilized amorphous lorcaserin hydrochloride
WO2015096119A1 (zh) * 2013-12-27 2015-07-02 杭州普晒医药科技有限公司 氯卡色林盐及其晶体、其制备方法和用途
WO2015161730A1 (zh) 2014-04-21 2015-10-29 杭州普晒医药科技有限公司 一种氯卡色林共晶及其制备方法、药物组合物和用途
CN103901151A (zh) * 2014-04-23 2014-07-02 湖北朗昕生化药业有限公司 一种hplc法检测氯卡色林盐酸盐含量的方法
WO2016069875A1 (en) 2014-10-30 2016-05-06 Arena Pharmaceuticals, Inc. Compositions and methods for ceasing tobacco smoking
CN109475586A (zh) 2016-06-29 2019-03-15 康纳塞斯创新公司 脱羧的大麻树脂、其用途和制备其的方法

Family Cites Families (53)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2561916B1 (fr) 1984-03-30 1987-12-11 Lafon Labor Forme galenique pour administration orale et son procede de preparation par lyophilisation d'une emission huile dans eau
US4642903A (en) 1985-03-26 1987-02-17 R. P. Scherer Corporation Freeze-dried foam dosage form
US5073374A (en) 1988-11-30 1991-12-17 Schering Corporation Fast dissolving buccal tablet
US5112616A (en) 1988-11-30 1992-05-12 Schering Corporation Fast dissolving buccal tablet
US5219574A (en) 1989-09-15 1993-06-15 Cima Labs. Inc. Magnesium carbonate and oil tableting aid and flavoring additive
US5178878A (en) 1989-10-02 1993-01-12 Cima Labs, Inc. Effervescent dosage form with microparticles
US5223264A (en) 1989-10-02 1993-06-29 Cima Labs, Inc. Pediatric effervescent dosage form
US5188825A (en) 1989-12-28 1993-02-23 Iles Martin C Freeze-dried dosage forms and methods for preparing the same
JPH06508352A (ja) * 1991-06-21 1994-09-22 スミスクライン・ビーチャム・パブリック・リミテッド・カンパニー 門脈圧亢進症および片頭痛の治療用のテトラヒドロベンズアゼピン誘導体の使用
US5464632C1 (en) 1991-07-22 2001-02-20 Prographarm Lab Rapidly disintegratable multiparticular tablet
DE69331839T2 (de) 1992-01-29 2002-12-12 Takeda Chemical Industries, Ltd. Schnellösliche Tablette und ihre Herstellung
DE4203932A1 (de) 1992-02-11 1993-08-12 Deutsche Aerospace Sende-/empfangsmodul
US5503846A (en) 1993-03-17 1996-04-02 Cima Labs, Inc. Base coated acid particles and effervescent formulation incorporating same
DE69429119T2 (de) 1993-07-09 2002-07-18 R.P. Scherer Corp., Troy Verfahren zur herstellung von gefriergetrockneten arzneistoffdosierungsformen
US5851553A (en) 1993-09-10 1998-12-22 Fuisz Technologies, Ltd. Process and apparatus for making rapidly dissolving dosage units and product therefrom
US5622719A (en) 1993-09-10 1997-04-22 Fuisz Technologies Ltd. Process and apparatus for making rapidly dissolving dosage units and product therefrom
US5895664A (en) 1993-09-10 1999-04-20 Fuisz Technologies Ltd. Process for forming quickly dispersing comestible unit and product therefrom
US5595761A (en) 1994-01-27 1997-01-21 The Board Of Regents Of The University Of Oklahoma Particulate support matrix for making a rapidly dissolving tablet
US5576014A (en) 1994-01-31 1996-11-19 Yamanouchi Pharmaceutical Co., Ltd Intrabuccally dissolving compressed moldings and production process thereof
US5635210A (en) 1994-02-03 1997-06-03 The Board Of Regents Of The University Of Oklahoma Method of making a rapidly dissolving tablet
US5567439A (en) 1994-06-14 1996-10-22 Fuisz Technologies Ltd. Delivery of controlled-release systems(s)
GB9421836D0 (en) 1994-10-28 1994-12-14 Scherer Corp R P Process for preparing solid pharmaceutical dosage forms of hydrophobic substances
US5639475A (en) 1995-02-03 1997-06-17 Eurand America, Incorporated Effervescent microcapsules
US5607697A (en) 1995-06-07 1997-03-04 Cima Labs, Incorporated Taste masking microparticles for oral dosage forms
US5807577A (en) 1995-11-22 1998-09-15 Lab Pharmaceutical Research International Inc. Fast-melt tablet and method of making same
US5807578A (en) 1995-11-22 1998-09-15 Lab Pharmaceutical Research International Inc. Fast-melt tablet and method of making same
WO1998014179A1 (en) 1996-10-01 1998-04-09 Cima Labs Inc. Taste-masked microcapsule compositions and methods of manufacture
US6024981A (en) 1997-04-16 2000-02-15 Cima Labs Inc. Rapidly dissolving robust dosage form
US5869098A (en) 1997-08-20 1999-02-09 Fuisz Technologies Ltd. Fast-dissolving comestible units formed under high-speed/high-pressure conditions
US6316029B1 (en) 2000-05-18 2001-11-13 Flak Pharma International, Ltd. Rapidly disintegrating solid oral dosage form
GB0111186D0 (en) * 2001-05-08 2001-06-27 Smithkline Beecham Plc Novel compounds
US20030124028A1 (en) * 2001-08-10 2003-07-03 Carlson Eric D. Apparatuses and methods for creating and testing pre-formulations and systems for same
US6953787B2 (en) * 2002-04-12 2005-10-11 Arena Pharmaceuticals, Inc. 5HT2C receptor modulators
CA2482195A1 (en) 2002-04-12 2003-10-23 The University Of Chicago Farnesoid x-activated receptor agonists
EA016485B1 (ru) 2003-06-17 2012-05-30 Арена Фармасьютикалз, Инк. Способы получения 3-бензазепинов
CN1805938B (zh) * 2003-06-17 2010-06-16 艾尼纳制药公司 用于治疗5ht2c受体相关疾病的苯并氮杂卓衍生物
TW200510324A (en) * 2003-08-11 2005-03-16 Lilly Co Eli 6-(2,2,2-trifluoroethylamino)-7-chiloro-2, 3, 4, 5-tetrahydro-1h-benzo[d]azepine as a 5-ht2c receptor agonist
WO2005042491A1 (en) * 2003-10-22 2005-05-12 Arena Pharmaceuticals, Inc. Benzazepine derivatives and methods of prophylaxis or treatment of 5ht2c receptor associated diseases
EP2479168B1 (en) * 2004-02-25 2014-04-09 Eli Lilly And Company 6-Substituted 2,3,4,5-Tetrahydro-1H-Benzo [d]Azepines as 5-HT2C Receptor Agonists
EA201200954A1 (ru) * 2004-12-21 2013-05-30 Арена Фармасьютикалз, Инк. Способ получения полугидрата гидрохлорида (r)-8-хлор-1-метил-2,3,4,5-тетрагидро-1н-3-бензазепина, фармацевтическая композиция на его основе и его применение
PL1833473T3 (pl) * 2004-12-23 2010-02-26 Arena Pharm Inc Kompozycje modulatora receptora 5HT2C i sposoby zastosowania
MY148521A (en) 2005-01-10 2013-04-30 Arena Pharm Inc Substituted pyridinyl and pyrimidinyl derivatives as modulators of metabolism and the treatment of disorders related thereto
EP1924560B1 (en) * 2005-09-01 2009-08-05 Eli Lilly And Company 6-substituted- 2,3,4,5-tetrahydro-1h-benzo[d]azepines as 5-ht2c receptor agonists
WO2007028131A1 (en) * 2005-09-01 2007-03-08 Eli Lilly And Company 6-SUBSTITUTED 2,3,4,5-TETRAHYDRO-1H-BENZO[d]AZEPINES AS 5-HT2C RECEPTOR AGONISTS
CN101466684B (zh) 2006-04-03 2012-06-20 艾尼纳制药公司 8-氯-1-甲基-2,3,4,5-四氢-1h-3-苯并氮杂卓的制备工艺和其相关中间体
US8299241B2 (en) * 2006-12-05 2012-10-30 Arena Pharmaceuticals, Inc. Processes for preparing (R)-8-chloro-1-methyl-2,3,4,5-tetrahydro-1H-3-benzazepine and intermediates thereof
WO2008081204A1 (en) 2007-01-04 2008-07-10 Prosidion Limited Piperidine gpcr agonists
US20090143363A1 (en) * 2007-10-15 2009-06-04 Concert Pharmaceuticals, Inc. Deuterated lorcaserin
CN102015591B (zh) 2008-03-04 2014-01-29 艾尼纳制药公司 制备与5-ht2c激动剂(r)-8-氯-1-甲基-2,3,4,5-四氢-1h-3-苯并氮杂卓相关的中间体的方法
MX2010010562A (es) 2008-03-31 2010-12-07 Metabolex Inc Compuestos de oximetilen-arilo y uso de los mismos.
AU2009271414A1 (en) 2008-06-20 2010-01-21 Metabolex, Inc. Aryl GPR119 agonists and uses thereof
CA2736421A1 (en) 2008-09-10 2010-03-18 Boehringer Ingelheim International Gmbh Combination therapy for the treatment of diabetes and related conditions
MX2011013648A (es) 2009-06-24 2012-03-06 Boehringer Ingelheim Int Nuevos compuestos, composiciones farmaceuticas y metodos relacionados con ellos.

Also Published As

Publication number Publication date
EP2611781A1 (en) 2013-07-10
WO2012030951A1 (en) 2012-03-08
AU2011296027A1 (en) 2013-04-04
JP2013536858A (ja) 2013-09-26
CA2808900A1 (en) 2012-03-08
SG188363A1 (en) 2013-04-30
US20140148442A1 (en) 2014-05-29
SG10201506873WA (en) 2015-10-29
MX2013002430A (es) 2013-07-22
KR20130138768A (ko) 2013-12-19
CN103189358A (zh) 2013-07-03

Similar Documents

Publication Publication Date Title
IN2013DN02552A (enrdf_load_html_response)
WO2012030927A3 (en) Modified-release dosage forms of 5-ht2c agonists useful for weight management
PH12016500739B1 (en) Inhibitors of the fibrolast growth factor receptor
MY181898A (en) Heterocyclic compounds and uses thereof
MX367795B (es) Inhibidores de cdk.
GB201017345D0 (en) Receptor antagonists
MX355728B (es) Inhibidores de cinasas.
RS53818B1 (en) PIROLOBENZODIAZEPINI I NJIHOVI conjugated
MX2013002422A (es) Sales de lorcaserina con acidos opticamente activos.
PH12013500065A1 (en) Deuterated n-ethyl-n-phenyl-1,2-dihydro-4-hydroxy-5-chloro-1-methyl-2-oxoquinoline-3-carboxamide, salts and uses thereof
UY34763A (es) Inhibidores de la agregación plaquetaria
PH12014501273A1 (en) Intranasal dexmedetomidine compositions and methods of use thereof
UY34559A (es) Inhibidores de bromodominios
IN2012DN06714A (enrdf_load_html_response)
MX2013008390A (es) Preparacion de estructuras de metal-triazolato.
UY34216A (es) Nuevos compuestos que inhiben la actividad de la Lp-PLA2
TW201144301A (en) Processes for preparing linezolid
MY165118A (en) Method for preparation of 2-(2,3-dimethylphenyl)-1-propanal with chloroacetone
MA34075B1 (fr) Composition pharmaceutique comprenant un dérivé pyrimidineone
PH12016500347A1 (en) Triazolopyridine compounds, compositions and methods of use thereof
MX2013002421A (es) Sales no hidroscopicas de agonistas de 5-ht2c.
IN2014DN11078A (enrdf_load_html_response)
ZA201505170B (en) Tablets with improved acceptance and good storage stability
IT1400702B1 (it) Apparecchiatura per l'imballaggio di carichi con pellicola termoretraibile, dotata di bruciatori regolabili.
UA51902U (ru) Применение антагониста рецепторов интерлейкина-1 (арил-1) в качестве способа фригопротекторного действия